CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Clinical trial NCT06081478 · RECRUITING

Trial details

NCT number: NCT06081478
Sponsor: Beijing Tongren Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia B-cell Lymphoma Diffuse Large B Cell Lymphoma

Start date: 2022-01-18
Primary completion: 2025-12-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.